MX2020002810A - Composicion inmunogenica de citomegalovirus humano. - Google Patents

Composicion inmunogenica de citomegalovirus humano.

Info

Publication number
MX2020002810A
MX2020002810A MX2020002810A MX2020002810A MX2020002810A MX 2020002810 A MX2020002810 A MX 2020002810A MX 2020002810 A MX2020002810 A MX 2020002810A MX 2020002810 A MX2020002810 A MX 2020002810A MX 2020002810 A MX2020002810 A MX 2020002810A
Authority
MX
Mexico
Prior art keywords
immunogenic composition
human cytomegalovirus
hcmv
antigen
relates
Prior art date
Application number
MX2020002810A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Chaux
Rafaela Dumas
Jean Haensler
Sylvie Pichon
Fabienne Piras-Douce
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2020002810A publication Critical patent/MX2020002810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2020002810A 2017-09-13 2018-09-11 Composicion inmunogenica de citomegalovirus humano. MX2020002810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306179 2017-09-13
PCT/EP2018/074369 WO2019052975A1 (en) 2017-09-13 2018-09-11 IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS

Publications (1)

Publication Number Publication Date
MX2020002810A true MX2020002810A (es) 2020-07-21

Family

ID=60782111

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002810A MX2020002810A (es) 2017-09-13 2018-09-11 Composicion inmunogenica de citomegalovirus humano.

Country Status (13)

Country Link
US (4) US11524069B2 (enExample)
EP (1) EP3681534A1 (enExample)
JP (2) JP7770767B2 (enExample)
KR (2) KR20250006307A (enExample)
CN (1) CN111344009A (enExample)
AU (1) AU2018331874B2 (enExample)
BR (1) BR112020004747A2 (enExample)
CA (1) CA3075207A1 (enExample)
IL (1) IL273120B2 (enExample)
MX (1) MX2020002810A (enExample)
SG (1) SG11202002174SA (enExample)
WO (1) WO2019052975A1 (enExample)
ZA (1) ZA202001561B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020004747A2 (pt) 2017-09-13 2020-09-24 Sanofi Pasteur composição imunogênica de citomegalovírus humano
JP7179872B2 (ja) * 2018-12-10 2022-11-29 Ｋｍバイオロジクス株式会社 サイトメガロウイルスの先天性感染を予防又は治療するためのワクチン
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4237085A1 (en) * 2020-10-28 2023-09-06 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
WO2024218752A1 (en) * 2023-04-21 2024-10-24 Instar Technologies A.S. Pharmaceutical composition for vaccination against cytomegalovirus infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US20020102562A1 (en) 1995-05-24 2002-08-01 Pasteur Merieux Serums Et Vaccines S.A. Recombinant CMV neutralizing proteins
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
WO2004060396A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Immunogenic compositions containing phospholpid
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
ATE549031T1 (de) * 2007-09-21 2012-03-15 Sanofi Pasteur Impfstoffzusammensetzung zur prävention von cmv- infektionen
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
CA2814386C (en) * 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
AR083454A1 (es) 2010-10-15 2013-02-27 Glaxosmithkline Biolog Sa Antigeno de citomegalovirus
WO2012141984A1 (en) * 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2729168A2 (en) * 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
MX378747B (es) 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
AU2013293570B2 (en) * 2012-07-27 2019-05-23 City Of Hope An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
US20150359879A1 (en) * 2012-10-30 2015-12-17 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
US20170119874A1 (en) * 2014-04-23 2017-05-04 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
EP3139953A1 (en) 2014-05-08 2017-03-15 Pfizer Inc. Means and methods for treating cmv
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
WO2017044895A2 (en) * 2015-09-10 2017-03-16 City Of Hope MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
MA46316A (fr) * 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
HRP20250077T1 (hr) * 2016-06-17 2025-03-28 Boehringer Ingelheim Vetmedica Gmbh Nove imunogene formulacije koje sadrže ravne ili razgranate polimerne adjuvante poliakrilne kiseline
BR112020004747A2 (pt) 2017-09-13 2020-09-24 Sanofi Pasteur composição imunogênica de citomegalovírus humano

Also Published As

Publication number Publication date
WO2019052975A1 (en) 2019-03-21
RU2020113253A (ru) 2021-10-18
IL273120B1 (en) 2023-06-01
WO2019052975A9 (en) 2020-04-09
ZA202001561B (en) 2021-07-28
US11524069B2 (en) 2022-12-13
AU2018331874B2 (en) 2022-06-02
US20200276301A1 (en) 2020-09-03
RU2020113253A3 (enExample) 2021-11-17
JP2024026160A (ja) 2024-02-28
US11207403B2 (en) 2021-12-28
JP7770767B2 (ja) 2025-11-17
SG11202002174SA (en) 2020-04-29
JP2020533354A (ja) 2020-11-19
IL273120A (en) 2020-04-30
US20250228933A1 (en) 2025-07-17
BR112020004747A2 (pt) 2020-09-24
EP3681534A1 (en) 2020-07-22
NZ763438A (en) 2025-03-28
KR20250006307A (ko) 2025-01-10
IL273120B2 (en) 2023-10-01
US20210023202A1 (en) 2021-01-28
KR20200051778A (ko) 2020-05-13
CA3075207A1 (en) 2019-03-21
AU2018331874A1 (en) 2020-04-30
CN111344009A (zh) 2020-06-26
US20230277655A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2020002810A (es) Composicion inmunogenica de citomegalovirus humano.
EP4028030A4 (en) VACCINE AGAINST HUMAN CYTOMEGALOVIRUS
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
WO2015103167A3 (en) Single vial vaccine formulations
PH12018501602A1 (en) Subunit immersion vaccines for fish
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
MX2015010783A (es) Composicion de vacuna.
HK1252967A1 (zh) 治疗性hpv18疫苗
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
IL277129A (en) Human papillomavirus vaccines and their uses
EP3717511A4 (en) ZIKA VIRUS VACCINES, IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES
MX2019007973A (es) Composiciones universales de vacuna de la influenza.
EP3347045A4 (en) MVA-GH / GL-PC VACCINATED ANTIBODIES FOR NEUTRALIZING THE INFECTIOSITY OF HUMAN CYTOMEGALOVIRUS AND METHOD THEREFOR
HK1254522A1 (zh) 灭活的犬流感疫苗以及其制备方法和用途
WO2017196819A3 (en) Broadly neutralizing anti-human cytomegalovirus (hcmv) antibodies and methods of use thereof
WO2017053525A3 (en) Influenza vaccine and therapy
WO2019099578A8 (en) Use of imidazopyrimidine for modulating human immune response
IL280335A (en) A new attenuated virus strain and its use as a vaccine
WO2015196180A3 (en) Influenza vaccines and methods of use thereof
AU2019902524A0 (en) Immunogenic Vaccines and uses thereof
HK40103030A (zh) 寨卡疫苗和免疫原性组合物以及其使用方法
HK40103231A (zh) 寨卡疫苗和免疫原性组合物以及其使用方法
HK40044077A (en) Human papillomavirus vaccines and uses of the same